Comparative evaluation of the effects of labetalol, verapamil and diltiazem on antipyrine and indocyanine green clearances. 1989

M L Rocci, and P H Vlasses, and M E Lener, and R A Fruncillo, and M A Sirgo
Division of Clinical Pharmacology, Jefferson Medical College, Philadelphia, PA.

The effects of labetalol, diltiazem and verapamil on antipyrine and indocyanine green clearance were evaluated in a placebo-controlled, repeated measures evaluation. Twelve healthy subjects received either labetalol (200 mg every 12 hours), diltiazem (90 mg. every 8 hours), verapamil (80 mg every 8 hours), or placebo (every 12 hours) for 4 days. On the morning of Day 3 immediately following their dose, the subjects assumed the supine position for 90 minutes, after which time a 0.5 mg/kg dose of indocyanine green was administered. Blood samples were obtained serially over a 20 minutes period for indocyanine green plasma concentration determinations by HPLC. Ten minutes later, subjects ingested a 1.2 Gm. dose of antipyrine and blood samples were obtained over a 48 hour period for antipyrine plasma concentration determinations by HPLC. A 2 week washout period separated treatment sequences. Mean (SD) antipyrine clearance (L/hr/kg) following diltiazem [0.028 (0.010)] and verapamil [0.030 (0.012)] treatment was significantly lower than that observed following placebo [0.039 (0.012)]. Antipyrine clearance following labetalol administration [0.033 (0.010)] was not significantly different from that observed following placebo, diltiazem or verapamil administration. No effects of these drugs on indocyanine green clearance could be detected.

UI MeSH Term Description Entries
D007208 Indocyanine Green A tricarbocyanine dye that is used diagnostically in liver function tests and to determine blood volume and cardiac output. Cardio-Green,Cardiogreen,Ujoveridin,Vofaverdin,Vophaverdin,Wofaverdin,Cardio Green,Green, Indocyanine
D007741 Labetalol A salicylamide derivative that is a non-cardioselective blocker of BETA-ADRENERGIC RECEPTORS and ALPHA-1 ADRENERGIC RECEPTORS. AH-5158,Albetol,Apo-Labetalol,Dilevalol,Labetalol Hydrochloride,Labetalol, (R,R)-Isomer,Labetolol,Normodyne,Presolol,R,R-Labetalol,SCH-19927,Trandate,AH 5158,AH5158,Apo Labetalol,ApoLabetalol,Hydrochloride, Labetalol,R,R Labetalol,SCH 19927,SCH19927
D008297 Male Males
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D004110 Diltiazem A benzothiazepine derivative with vasodilating action due to its antagonism of the actions of CALCIUM ion on membrane functions. Aldizem,CRD-401,Cardil,Cardizem,Dilacor,Dilacor XR,Dilren,Diltiazem Hydrochloride,Diltiazem Malate,Dilzem,Tiazac,CRD 401,CRD401
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000983 Antipyrine An analgesic and antipyretic that has been given by mouth and as ear drops. Antipyrine is often used in testing the effects of other drugs or diseases on drug-metabolizing enzymes in the liver. (From Martindale, The Extra Pharmacopoeia, 30th ed, p29) Phenazone,Anodynin,Pyramidone
D014700 Verapamil A calcium channel blocker that is a class IV anti-arrhythmia agent. Iproveratril,Calan,Cordilox,Dexverapamil,Falicard,Finoptin,Isoptin,Isoptine,Izoptin,Lekoptin,Verapamil Hydrochloride,Hydrochloride, Verapamil

Related Publications

M L Rocci, and P H Vlasses, and M E Lener, and R A Fruncillo, and M A Sirgo
October 1990, Clinical pharmacology and therapeutics,
M L Rocci, and P H Vlasses, and M E Lener, and R A Fruncillo, and M A Sirgo
August 1986, Clinical pharmacology and therapeutics,
M L Rocci, and P H Vlasses, and M E Lener, and R A Fruncillo, and M A Sirgo
May 1995, Xenobiotica; the fate of foreign compounds in biological systems,
M L Rocci, and P H Vlasses, and M E Lener, and R A Fruncillo, and M A Sirgo
February 1992, Journal of clinical pharmacology,
M L Rocci, and P H Vlasses, and M E Lener, and R A Fruncillo, and M A Sirgo
March 1995, Clinical pharmacology and therapeutics,
M L Rocci, and P H Vlasses, and M E Lener, and R A Fruncillo, and M A Sirgo
August 1988, Clinical pharmacology and therapeutics,
M L Rocci, and P H Vlasses, and M E Lener, and R A Fruncillo, and M A Sirgo
January 1983, The American journal of cardiology,
M L Rocci, and P H Vlasses, and M E Lener, and R A Fruncillo, and M A Sirgo
April 1983, American journal of veterinary research,
M L Rocci, and P H Vlasses, and M E Lener, and R A Fruncillo, and M A Sirgo
April 1983, American journal of veterinary research,
M L Rocci, and P H Vlasses, and M E Lener, and R A Fruncillo, and M A Sirgo
August 1995, American journal of therapeutics,
Copied contents to your clipboard!